Antigen-specific cytokine profiles for pulmonary Mycobacterium avium complex disease stage diagnosis

Front Immunol. 2023 Jul 14:14:1222428. doi: 10.3389/fimmu.2023.1222428. eCollection 2023.

Abstract

Introduction: Controlling pulmonary Mycobacterium avium complex (MAC) disease is difficult because there is no way to know the clinical stage accurately. There have been few attempts to use cell-mediated immunity for diagnosing the stage. The objective of this study was to characterize cytokine profiles of CD4+T and CD19+B cells that recognize various Mycobacterium avium-associated antigens in different clinical stages of MAC.

Methods: A total of 47 MAC patients at different stages based on clinical information (14 before-treatment, 16 on-treatment, and 17 after-treatment) and 17 healthy controls were recruited. Peripheral blood mononuclear cells were cultured with specific antigens (MAV0968, 1160, 1276, and 4925), and the cytokine profiles (IFN-γ, TNF-α, IL-2, IL-10, IL-13, and IL-17) of CD4+/CD3+ and CD19+ cells were analyzed by flow cytometry.

Results: The response of Th1 cytokines such as IFN-γ and TNF-α against various antigens was significantly higher in both the on-treatment and after-treatment groups than in the before-treatment group and control (P < 0.01-0.0001 and P < 0.05-0.0001). An analysis of polyfunctional T cells suggested that the presence of IL-2 is closely related to the stage after the start of treatment (P = 0.0309-P < 0.0001) and is involved in memory function. Non-Th1 cytokines, such as IL-10 and IL-17, showed significantly higher responses in the before-treatment group (P < 0.0001 and P < 0.01-0.0001). These responses were not observed with purified protein derivative (PPD). CD19+B cells showed a response similar to that of CD4+T cells.

Conclusion: There is a characteristic cytokine profile at each clinical stage of MAC.

Keywords: CD19+B cells; CD4+T cells; Mycobacterium avium complex disease; Mycobacterium avium-associated antigens; cell-mediated immunity; clinical stage; cytokine profile.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytokines
  • Humans
  • Interleukin-10
  • Interleukin-17
  • Interleukin-2 / therapeutic use
  • Leukocytes, Mononuclear
  • Lung Diseases*
  • Mycobacterium avium Complex
  • Mycobacterium avium-intracellulare Infection*
  • Tumor Necrosis Factor-alpha / therapeutic use

Substances

  • Interleukin-10
  • Interleukin-17
  • Interleukin-2
  • Tumor Necrosis Factor-alpha
  • Cytokines

Grants and funding

This study was supported by the Tenure track funds provided by Nagasaki University and Research Program on Emerging and Re-emerging Infectious Diseases under the Japan Agency for Medical Research and Development, AMED (number: JP23fk0108673).